Brief: Catalyst Biosciences Inc Says On April 4 Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
07/04/2023 21:23
April 7 (Reuters) - Catalyst Biosciences Inc CBIO.O :
* CATALYST BIOSCIENCES INC- ON APRIL 4 GOT NOTICE OF
DELISTING OR
FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD FROM
NASDAQ
Source text for Eikon: ID:
Further company coverage: CBIO.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes